HETEROCYCLES

Heterocycles has a pay-per-view service for Non-subscribers.
You will be able to directly purchase the full text article through PayPal.
Your purchased Paper can be downloaded after the payment is completed.
An e-mail will be sent the URL to download the paper.
If you have any questions, please contact: purchase@heterocycles.com

Price: ¥ 4,400 (Yen only)
Period: This Article can be accessed for 7 days.

■ Synthesis of 10b(R)-Hydroxypancratistatin, 10b(S)-Hydroxy-1-epipancratistatin, 10b(S)-Hydroxy-1,2-diepipancratistatin and Related Isocarbostyrils

George R. Pettit,* Noeleen Melody, Delbert L. Herald, Jean M. Schmidt, Robin K. Pettit, and Jean-Charles Chapuis

*Cancer Research Institute, Department of Chemistry and Biochemistry, Arizona State University, Main Campus, P.O. Box 872404, Tempe, AZ 85287-2404, U.S.A.

Abstract

Narciclasine (2) was transformed by a series of reactions where Sharpless asymmetric hydroxylations served as the stereochemical controlling step to 10b(R)-hydroxypancratistatin (3), 10b(S)-hydroxy-1-epipancratistatin (13) and 10b(S)-hydroxy-1,2-diepipancratistatin (16). Synthesis of 10b(S)-hydroxy-1,2-diepipancratistatin (16) proceeded from α-triol (11) via cyclic sulfate (14) and inversion of C-2 with cesium benzoate followed by saponification and treatment with a catalytic amount of acid. Compared to pancratistatin (1), these structural modifications led to decreased cancer cell growth inhibition against a mini-panel of human cancer cell lines. Narciclasine (2) inhibited the pathogenic yeast Cryptococcus neoformans, and modifications (4, 14 and 15) inhibited growth of the pathogenic bacterium Neisseria gonorrhoeae.